DMAC · DiaMedica Therapeutics Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 11, 2026TL;DR. DiaMedica reported positive Phase 2 late-onset preeclampsia Part 1a extension data with statistically significant blood pressure reductions, completed enrollment in the first cohort of its Phase 2 early-onset fetal growth restriction trial, and advanced the ReMEDy2 acute ischemic stroke Phase 2/3 trial past 85% of interim enrollment with readout now expected in Q1 2027. Net loss widened and R&D spending rose versus the prior-year period, while cash and short-term investments stood at $43.5 million with runway stated through 2027.
- + Enrollment completed in the first cohort of the Phase 2 early-onset fetal growth restriction trial, the first use of DM199 in this indication
- + ReMEDy2 acute ischemic stroke Phase 2/3 trial surpassed 85% of the 200-patient interim analysis enrollment threshold
- + Health Canada authorized and FDA pathway clarified to support opening of global Phase 2 early-onset preeclampsia sites, with U.S. IND pending a rat study
- + Stated cash runway extends through 2027 to fund planned clinical studies and corporate operations
- − Net loss widened to $10.1M in Q2 and $20.2M for the six months from $7.7M and $15.4M a year earlier
- − ReMEDy2 enrollment slowed in July and the interim analysis readout shifted to Q1 2027
- − Cash and short-term investments declined to $43.5M at June 30, 2026 from $59.9M at year-end 2025, with $17.2M used in operating activities in H1
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMAC
this stock
DiaMedica Therapeutics Inc.
|
$461.60M | +3.4% | — | — | 10.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMAC | +3.7% | +25.5% | +30.6% | -0.5% | +3.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +3.9% | +25.9% | +18.5% | -1.4% | -9.5% |